{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:48:26Z","timestamp":1768448906375,"version":"3.49.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,14]]},"DOI":"10.7759\/cureus.101535","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:04:03Z","timestamp":1768410243000},"source":"Crossref","is-referenced-by-count":0,"title":["Recent Updates and Advancements in the Diagnosis and Management of Plasma Cell Dyscrasias"],"prefix":"10.7759","author":[{"given":"Anand","family":"Sunil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahnaf Uddin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Elkhider Ali","family":"Musa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzoo","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafrin","family":"Kormath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Lahari","family":"Sangaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nejma","family":"Azeez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bashir","family":"Imam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Dontul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sweta","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Attia Hussein Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081961","article-title":"A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics","volume":"10","author":"Awada H","year":"2021","unstructured":"Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal B. A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics. Cells. 2021, 10:6. 10.3390\/cells10081961","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136166","article-title":"Primary plasma cell leukemia: recent advances in molecular understanding and treatment approaches","volume":"26","author":"Hanamura I","year":"2025","unstructured":"Hanamura I, Karnan S, Ota A, Takami A. Primary plasma cell leukemia: recent advances in molecular understanding and treatment approaches. Int J Mol Sci. 2025, 26:6. 10.3390\/ijms26136166","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22240-2","article-title":"Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021","volume":"25","author":"Diao X","year":"2025","unstructured":"Diao X, Ben T, Cheng S, Niu S, Gao L, Xia N. Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health. 2025, 25:1054. 10.1186\/s12889-025-22240-2","journal-title":"BMC Public Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2144056","article-title":"Systematic literature review of health economic models developed for multiple myeloma to support future analyses","volume":"26","author":"Choon-Quinones M","year":"2023","unstructured":"Choon-Quinones M, Zelei T, N\u00e9meth B, et al.. Systematic literature review of health economic models developed for multiple myeloma to support future analyses. J Med Econ. 2023, 26:110-9. 10.1080\/13696998.2022.2144056","journal-title":"J Med Econ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.S7-A.19","article-title":"Economic and clinical impact of multiple myeloma to managed care","volume":"14","author":"Cook R","year":"2008","unstructured":"Cook R. Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm. 2008, 14:19-25. 10.18553\/jmcp.2008.14.S7-A.19","journal-title":"J Manag Care Pharm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8777.1","article-title":"Recent advances in understanding multiple myeloma","volume":"5","author":"Dhakal B","year":"2016","unstructured":"Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Res. 2016, 5:7. 10.12688\/f1000research.8777.1","journal-title":"F1000Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09593-1","article-title":"Hybrid simultaneous whole-body 2-[(18)F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results","volume":"33","author":"Jamet B","year":"2023","unstructured":"Jamet B, Carlier T, Bailly C, et al.. Hybrid simultaneous whole-body 2-[(18)F]FDG-PET\/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results. Eur Radiol. 2023, 33:6438-47. 10.1007\/s00330-023-09593-1","journal-title":"Eur Radiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-025-02036-5","article-title":"Ga-68 Pentixafor PET\/CT in multiple myeloma and its correlation with clinical parameters: institutional pilot study","volume":"39","author":"Gauthaman DK","year":"2025","unstructured":"Gauthaman DK, Muthukrishnan I, Acharya KA, Simon S. Ga-68 Pentixafor PET\/CT in multiple myeloma and its correlation with clinical parameters: institutional pilot study. Ann Nucl Med. 2025, 39:588-99. 10.1007\/s12149-025-02036-5","journal-title":"Ann Nucl Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.30476\/ijms.2024.101739.3446","article-title":"Advancing multiple myeloma immunotherapy: a review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment","volume":"50","author":"Navab R","year":"2025","unstructured":"Navab R, Futela P, Kumari V, Valecha J, Gupta RB, Jain R. Advancing multiple myeloma immunotherapy: a review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment. Iran J Med Sci. 2025, 50:1-10. 10.30476\/ijms.2024.101739.3446","journal-title":"Iran J Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee H","year":"2023","unstructured":"Lee H, Neri P, Bahlis NJ. Current use of bispecific antibodies to treat multiple myeloma. Hematology Am Soc Hematol Educ Program. 2023, 2023:332-9. 10.1182\/hematology.2023000433","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.07.024","article-title":"Detection of plasma cell disorders by mass spectrometry: a comprehensive review of 19,523 cases","volume":"97","author":"Dasari S","year":"2022","unstructured":"Dasari S, Kohlhagen MC, Dispenzieri A, et al.. Detection of plasma cell disorders by mass spectrometry: a comprehensive review of 19,523 cases. Mayo Clin Proc. 2022, 97:294-307. 10.1016\/j.mayocp.2021.07.024","journal-title":"Mayo Clin Proc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray DL","year":"2021","unstructured":"Murray DL, Puig N, Kristinsson S, et al.. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021, 11:24. 10.1038\/s41408-021-00408-4","journal-title":"Blood Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A personalized mass spectrometry-based assay to monitor m-protein in patients with multiple myeloma (EasyM)","volume":"27","author":"Liyasova M","year":"2021","unstructured":"Liyasova M, McDonald Z, Taylor P, et al.. A personalized mass spectrometry-based assay to monitor m-protein in patients with multiple myeloma (EasyM). Clin Cancer Res. 2021, 27:5028-37. 10.1158\/1078-0432.CCR-21-0649","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqad137","article-title":"Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy","volume":"161","author":"Treger RS","year":"2024","unstructured":"Treger RS, Mathias PC, Cowan AJ, et al.. Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy. Am J Clin Pathol. 2024, 161:216-31. 10.1093\/ajcp\/aqad137","journal-title":"Am J Clin Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122930","article-title":"A cohort study of free light chain ratio in combination with serum protein electrophoresis as a first-line test in general practice","volume":"14","author":"Sandfeld-Paulsen B","year":"2022","unstructured":"Sandfeld-Paulsen B, Aggerholm-Pedersen N, Samson MH, M\u00f8ller HJ. A cohort study of free light chain ratio in combination with serum protein electrophoresis as a first-line test in general practice. Cancers (Basel). 2022, 14:3. 10.3390\/cancers14122930","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01340-7","article-title":"Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis","volume":"15","author":"Askari E","year":"2025","unstructured":"Askari E, Dispenzieri A, Buadi FK, et al.. Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis. Blood Cancer J. 2025, 15:133. 10.1038\/s41408-025-01340-7","journal-title":"Blood Cancer J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.154070","article-title":"Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents","volume":"102","author":"Tacchetti P","year":"2017","unstructured":"Tacchetti P, Pezzi A, Zamagni E, et al.. Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. Haematologica. 2017, 102:e104-7. 10.3324\/haematol.2016.154070","journal-title":"Haematologica"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01113-8","article-title":"Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms","volume":"14","author":"Jevremovic D","year":"2024","unstructured":"Jevremovic D, Shi M, Horna P, et al.. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms. Blood Cancer J. 2024, 14:126. 10.1038\/s41408-024-01113-8","journal-title":"Blood Cancer J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero J","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, et al.. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017, 31:2094-103. 10.1038\/leu.2017.29","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva S","year":"2023","unstructured":"Oliva S, Genuardi E, Paris L, et al.. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. EClinicalMedicine. 2023, 60:102016. 10.1016\/j.eclinm.2023.102016","journal-title":"EClinicalMedicine"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass J","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, et al.. International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019, 20:302-12. 10.1016\/S1470-2045(19)30309-2","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7150\/thno.16576","article-title":"[(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values","volume":"7","author":"Lapa C","year":"2017","unstructured":"Lapa C, Schreder M, Schirbel A, et al.. [(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values. Theranostics. 2017, 7:205-12. 10.7150\/thno.16576","journal-title":"Theranostics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou C","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S, et al.. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology. 2019, 291:5-13. 10.1148\/radiol.2019181949","journal-title":"Radiology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06668-z","article-title":"Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [(18)F]FDG PET\/CT predicts survival in multiple myeloma","volume":"51","author":"Sachpekidis C","year":"2024","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, et al.. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [(18)F]FDG PET\/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024, 51:2293-307. 10.1007\/s00259-024-06668-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01189-3","article-title":"Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma","volume":"7","author":"Hussain Z","year":"2024","unstructured":"Hussain Z, De Brouwer E, Boiarsky R, et al.. Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma. NPJ Digit Med. 2024, 7:200. 10.1038\/s41746-024-01189-3","journal-title":"NPJ Digit Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005815","article-title":"IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells","volume":"10","author":"Kehl N","year":"2022","unstructured":"Kehl N, Kilian M, Michel J, et al.. IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. J Immunother Cancer. 2022, 10:5. 10.1136\/jitc-2022-005815","journal-title":"J Immunother Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1515\/almed-2021-0087","article-title":"IgE multiple myeloma: detection and follow-up","volume":"3","author":"Nafr\u00eda Jim\u00e9nez B","year":"2022","unstructured":"Nafr\u00eda Jim\u00e9nez B, Oliveros Conejero R. IgE multiple myeloma: detection and follow-up. Adv Lab Med. 2022, 3:79-90. 10.1515\/almed-2021-0087","journal-title":"Adv Lab Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4103\/ijh.ijh_56_22","article-title":"Biclonal gammopathy - a single-center experience","volume":"12","author":"Narayanan G","year":"2023","unstructured":"Narayanan G, Thambi SM, Prabhakaran PK, et al.. Biclonal gammopathy - a single-center experience. Iraqi J Hematol. 2023, 12:38-43. 10.4103\/ijh.ijh_56_22","journal-title":"Iraqi J Hematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14111135","article-title":"Autoimmune diseases and plasma cell dyscrasias: pathogenetic, molecular and prognostic correlations","volume":"14","author":"Giordano L","year":"2024","unstructured":"Giordano L, Cacciola R, Barone P, et al.. Autoimmune diseases and plasma cell dyscrasias: pathogenetic, molecular and prognostic correlations. Diagnostics (Basel). 2024, 14:5. 10.3390\/diagnostics14111135","journal-title":"Diagnostics (Basel)"},{"key":"ref30","article-title":"Monoclonal gammopathy with significance: case series and literature review","volume":"78","author":"Schoot TS","year":"2020","unstructured":"Schoot TS, van Apeldoorn M, Sinnige HA, Beutler JJ. Monoclonal gammopathy with significance: case series and literature review. Neth J Med. 2020, 78:191-5.","journal-title":"Neth J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"31","author":"Buxbaum JN","year":"2024","unstructured":"Buxbaum JN, Eisenberg DS, F\u00e4ndrich M, et al.. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024, 31:249-56. 10.1080\/13506129.2024.2405948","journal-title":"Amyloid"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02489-z","article-title":"Capillary leak phenotype as a major cause of death in patients with POEMS syndrome","volume":"39","author":"Lee K","year":"2025","unstructured":"Lee K, Kourelis T, Tschautscher M, et al.. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome. Leukemia. 2025, 39:703-9. 10.1038\/s41375-024-02489-z","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20230927-00580","article-title":"The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma","volume":"104","author":"Shi QL","year":"2024","unstructured":"Shi QL, Xu Y, Wang J, Jin YY, Zhang R, Li JY, Chen LJ. The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma. Zhonghua Yi Xue Za Zhi. 2024, 104:514-20. 10.3760\/cma.j.cn112137-20230927-00580","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030882","article-title":"Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents","volume":"96","author":"Fern\u00e1ndez de Larrea C","year":"2011","unstructured":"Fern\u00e1ndez de Larrea C, Tovar N, Cibeira MT, et al.. Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica. 2011, 96:171-3. 10.3324\/haematol.2010.030882","journal-title":"Haematologica"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos G","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, et al.. Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2023, 5:1-21. 10.1016\/j.jaccao.2022.12.005","journal-title":"JACC CardioOncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240318","article-title":"Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials","volume":"13","author":"Ye L","year":"2023","unstructured":"Ye L, Zhou F, Cheng D, et al.. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Front Oncol. 2023, 13:1240318. 10.3389\/fonc.2023.1240318","journal-title":"Front Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt H","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, et al.. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022, 9:810-21. 10.1016\/S2352-3026(22)00263-0","journal-title":"Lancet Haematol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees PM","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al.. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020, 136:936-45. 10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01120-9","article-title":"Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients","volume":"14","author":"Joseph NS","year":"2024","unstructured":"Joseph NS, Kaufman JL, Gupta VA, et al.. Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood Cancer J. 2024, 14:159. 10.1038\/s41408-024-01120-9","journal-title":"Blood Cancer J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser MF","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, et al.. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J Clin Oncol. 2023, 41:3945-55. 10.1200\/JCO.22.02567","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra S","year":"2023","unstructured":"Chhabra S, Callander N, Watts NL, et al.. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2023, 29:174.e1-e10. 10.1016\/j.jtct.2022.11.029","journal-title":"Transplant Cell Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar SV","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024, 99:1802-24. 10.1002\/ajh.27422","journal-title":"Am J Hematol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.030","article-title":"Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era: real-world results from the Canadian Myeloma Research Group database","volume":"30","author":"Venner CP","year":"2024","unstructured":"Venner CP, Duggan P, Song K, et al.. Tandem autologous stem cell transplantation does not benefit high-risk myeloma patients in the maintenance era: real-world results from the Canadian Myeloma Research Group database. Transplant Cell Ther. 2024, 30:889-901. 10.1016\/j.jtct.2024.06.030","journal-title":"Transplant Cell Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros A","year":"2025","unstructured":"Badros A, Foster L, Anderson LD Jr, et al.. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025, 145:300-10. 10.1182\/blood.2024025746","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al.. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021, 384:705-16. 10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15556","article-title":"Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort","volume":"113","author":"Ri M","year":"2022","unstructured":"Ri M, Suzuki K, Ishida T, et al.. Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Cancer Sci. 2022, 113:4267-76. 10.1111\/cas.15556","journal-title":"Cancer Sci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.015","article-title":"Real-world outcomes of sequential BCMA-directed therapies in relapsed refractory multiple myeloma after belantamab exposure","volume":"25","author":"Mewawalla P","year":"2025","unstructured":"Mewawalla P, Dileo R, Yin Y, et al.. Real-world outcomes of sequential BCMA-directed therapies in relapsed refractory multiple myeloma after belantamab exposure. Clin Lymphoma Myeloma Leuk. 2025, 25:e1007-13. 10.1016\/j.clml.2025.06.015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0122","article-title":"Dual targeting with CAR T cells to limit antigen escape in multiple myeloma","volume":"1","author":"Simon S","year":"2020","unstructured":"Simon S, Riddell SR. Dual targeting with CAR T cells to limit antigen escape in multiple myeloma. Blood Cancer Discov. 2020, 1:130-3. 10.1158\/2643-3230.BCD-20-0122","journal-title":"Blood Cancer Discov"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03884-z","article-title":"A Phase 1\/2 study of teclistamab, a humanized BCMA\u2009\u00d7\u2009CD3 bispecific Ab in Japanese patients with relapsed\/refractory MM","volume":"121","author":"Ishida T","year":"2025","unstructured":"Ishida T, Kuroda Y, Matsue K, et al.. A Phase 1\/2 study of teclistamab, a humanized BCMA\u2009\u00d7\u2009CD3 bispecific Ab in Japanese patients with relapsed\/refractory MM. Int J Hematol. 2025, 121:222-31. 10.1007\/s12185-024-03884-z","journal-title":"Int J Hematol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35927","article-title":"Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"131","author":"Schinke C","year":"2025","unstructured":"Schinke C, Touzeau C, Oriol A, et al.. Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study. Cancer. 2025, 131:e35927. 10.1002\/cncr.35927","journal-title":"Cancer"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM- 2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial S","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al.. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM- 2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020, 21:207-21. 10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70013","article-title":"Vaccination in multiple myeloma: challenges and strategies","volume":"115","author":"Martino EA","year":"2025","unstructured":"Martino EA, Vigna E, Bruzzese A, et al.. Vaccination in multiple myeloma: challenges and strategies. Eur J Haematol. 2025, 115:334-43. 10.1111\/ejh.70013","journal-title":"Eur J Haematol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00456-5","article-title":"Immune checkpoint inhibitors for multiple myeloma immunotherapy","volume":"12","author":"Liu Z","year":"2023","unstructured":"Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023, 12:99. 10.1186\/s40164-023-00456-5","journal-title":"Exp Hematol Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon SP","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, et al.. Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia. N Engl J Med. 2015, 372:1430-40. 10.1056\/NEJMoa1501548","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang J","year":"2019","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019, 18:26. 10.1186\/s12943-019-0954-x","journal-title":"Mol Cancer"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis E","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al.. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021, 385:46-58. 10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards CV","year":"2021","unstructured":"Edwards CV, Rao N, Bhutani D, et al.. Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021, 138:2632-41. 10.1182\/blood.2020009039","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li Y","year":"2022","unstructured":"Li Y, Sun Z, Qu X. Advances in the treatment of extramedullary disease in multiple myeloma. Transl Oncol. 2022, 22:101465. 10.1016\/j.tranon.2022.101465","journal-title":"Transl Oncol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70112","article-title":"Clinical outcome of extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study","volume":"43","author":"Liang D","year":"2025","unstructured":"Liang D, Yan Y, Wang Q, et al.. Clinical outcome of extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study. Hematol Oncol. 2025, 43:e70112. 10.1002\/hon.70112","journal-title":"Hematol Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00218-5","article-title":"Defining FiTNEss for treatment for multiple myeloma","volume":"3","author":"Cook G","year":"2022","unstructured":"Cook G, Pawlyn C, Cairns DA, et al.. Defining FiTNEss for treatment for multiple myeloma. Lancet Healthy Longev. 2022, 3:729-30. 10.1016\/S2666-7568(22)00218-5","journal-title":"Lancet Healthy Longev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","volume":"10","author":"Murillo A","year":"2019","unstructured":"Murillo A, Cronin AM, Laubach JP, et al.. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geriatr Oncol. 2019, 10:486-9. 10.1016\/j.jgo.2018.10.010","journal-title":"J Geriatr Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15715","article-title":"Geriatric assessment in older adults with multiple myeloma","volume":"67","author":"Wildes TM","year":"2019","unstructured":"Wildes TM, Tuchman SA, Klepin HD, et al.. Geriatric assessment in older adults with multiple myeloma. J Am Geriatr Soc. 2019, 67:987-91. 10.1111\/jgs.15715","journal-title":"J Am Geriatr Soc"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3669","article-title":"Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines","volume":"10","author":"Manapuram S","year":"2018","unstructured":"Manapuram S, Hashmi H. Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines. Cureus. 2018, 10:e3669. 10.7759\/cureus.3669","journal-title":"Cureus"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark WF","year":"2005","unstructured":"Clark WF, Stewart AK, Rock GA, et al.. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005, 143:777-84. 10.7326\/0003-4819-143-11-200512060-00005","journal-title":"Ann Intern Med"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1024133","article-title":"High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury","volume":"12","author":"Xing Y","year":"2022","unstructured":"Xing Y, Yan J, Yu Z, et al.. High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury. Front Oncol. 2022, 12:1024133. 10.3389\/fonc.2022.1024133","journal-title":"Front Oncol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy065","article-title":"Treatment of multiple myeloma with renal involvement: the nephrologist's view","volume":"11","author":"Fav\u00e0 A","year":"2018","unstructured":"Fav\u00e0 A, Fulladosa X, Montero N, Draibe J, Torras J, Gom\u00e0 M, Cruzado JM. Treatment of multiple myeloma with renal involvement: the nephrologist's view. Clin Kidney J. 2018, 11:777-85. 10.1093\/ckj\/sfy065","journal-title":"Clin Kidney J"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000151","article-title":"High-cutoff hemodialysis therapy for patients with light chain cast nephropathy and aki requiring dialysis: PRO","volume":"4","author":"Latcha S","year":"2023","unstructured":"Latcha S, Leung N. High-cutoff hemodialysis therapy for patients with light chain cast nephropathy and aki requiring dialysis: PRO. Kidney360. 2023, 4:1021-3. 10.34067\/KID.0000000000000151","journal-title":"Kidney360"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185264","article-title":"Denosumab for bone lesions in multiple myeloma - what is its value?","volume":"103","author":"Goldstein DA","year":"2018","unstructured":"Goldstein DA. Denosumab for bone lesions in multiple myeloma - what is its value?. Haematologica. 2018, 103:753-4. 10.3324\/haematol.2017.185264","journal-title":"Haematologica"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos E","year":"2021","unstructured":"Terpos E, Raje N, Croucher P, et al.. Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood Adv. 2021, 5:725-36. 10.1182\/bloodadvances.2020002378","journal-title":"Blood Adv"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45270","article-title":"Multiple myeloma and the role of bisphosphonates in its management","volume":"15","author":"Tanveer N","year":"2023","unstructured":"Tanveer N, Hussein S, Pingili S, et al.. Multiple myeloma and the role of bisphosphonates in its management. Cureus. 2023, 15:e45270. 10.7759\/cureus.45270","journal-title":"Cureus"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116192","article-title":"Current novel targeted therapeutic strategies in multiple myeloma","volume":"25","author":"Lin CH","year":"2024","unstructured":"Lin CH, Tariq MJ, Ullah F, et al.. Current novel targeted therapeutic strategies in multiple myeloma. Int J Mol Sci. 2024, 25:2. 10.3390\/ijms25116192","journal-title":"Int J Mol Sci"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.4103\/jpbs.jpbs_560_22","article-title":"Therapeutic use of anti-sclerostin antibody in the treatment of multiple myeloma: a systematic review","volume":"15","author":"Ngomdir L","year":"2023","unstructured":"Ngomdir L, Bharathwaj VV, Nimmy P, et al.. Therapeutic use of anti-sclerostin antibody in the treatment of multiple myeloma: a systematic review. J Pharm Bioallied Sci. 2023, 15:S738-41. 10.4103\/jpbs.jpbs_560_22","journal-title":"J Pharm Bioallied Sci"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000414","article-title":"Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy","volume":"2022","author":"Covut F","year":"2022","unstructured":"Covut F, Sanfilippo KM. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy. Hematology Am Soc Hematol Educ Program. 2022, 2022:363-7. 10.1182\/hematology.2022000414","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102685","article-title":"Thromboprophylaxis in multiple myeloma","volume":"9","author":"Frenzel L","year":"2025","unstructured":"Frenzel L. Thromboprophylaxis in multiple myeloma. Res Pract Thromb Haemost. 2025, 9:102685. 10.1016\/j.rpth.2025.102685","journal-title":"Res Pract Thromb Haemost"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"De Stefano V","year":"2022","unstructured":"De Stefano V, Larocca A, Carpenedo M, et al.. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica. 2022, 107:2536-47. 10.3324\/haematol.2022.280893","journal-title":"Haematologica"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje NS","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, et al.. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022, 9:143-61. 10.1016\/S2352-3026(21)00283-0","journal-title":"Lancet Haematol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100476","article-title":"Supportive care in multiple myeloma: current practices and advances","volume":"29","author":"Miceli TS","year":"2021","unstructured":"Miceli TS, Gonsalves WI, Buadi FK. Supportive care in multiple myeloma: current practices and advances. Cancer Treat Res Commun. 2021, 29:100476. 10.1016\/j.ctarc.2021.100476","journal-title":"Cancer Treat Res Commun"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark C","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist UH, et al.. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015, 100:107-13. 10.3324\/haematol.2014.107714","journal-title":"Haematologica"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_4028_20","article-title":"Quality of life assessment & out-of-pocket expenditure in multiple myeloma: an observational study","volume":"154","author":"Mathew A","year":"2021","unstructured":"Mathew A, Farooqui HH, Kumar L. Quality of life assessment & out-of-pocket expenditure in multiple myeloma: an observational study. Indian J Med Res. 2021, 154:823-32. 10.4103\/ijmr.IJMR_4028_20","journal-title":"Indian J Med Res"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06129-5","article-title":"Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes","volume":"103","author":"Shah D","year":"2024","unstructured":"Shah D, Sparano F, Luo C, et al.. Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes. Ann Hematol. 2024, 103:5849-59. 10.1007\/s00277-024-06129-5","journal-title":"Ann Hematol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-024-01524-1","article-title":"A multidisciplinary group-based survivorship intervention for those living with multiple myeloma: a feasibility study","volume":"10","author":"Eilert N","year":"2024","unstructured":"Eilert N, Murphy NJ, Cummins H, Houlihan E, Krawczyk J. A multidisciplinary group-based survivorship intervention for those living with multiple myeloma: a feasibility study. Pilot Feasibility Stud. 2024, 10:100. 10.1186\/s40814-024-01524-1","journal-title":"Pilot Feasibility Stud"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-024-02447-w","article-title":"Integrating palliative care into multiple myeloma management : optimizing quality of life across the disease continuum","volume":"137","author":"R\u00fcsing L","year":"2025","unstructured":"R\u00fcsing L, Brunbauer C, Michel CS, et al.. Integrating palliative care into multiple myeloma management : optimizing quality of life across the disease continuum. Wien Klin Wochenschr. 2025, 137:351-6. 10.1007\/s00508-024-02447-w","journal-title":"Wien Klin Wochenschr"},{"key":"ref83","unstructured":"IMF Nurse Leadership Board. IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Multiple Myeloma. International Myeloma Foundation. (2025). Accessed. September 10, 2025: https:\/\/www.myeloma.org\/resource-library\/imf-nurse-leadership-board-nlb-survivorship-care-plan-multiple-myeloma."},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187609","article-title":"Meaningful changes in end-of-life care among patients with myeloma","volume":"103","author":"Odejide OO","year":"2018","unstructured":"Odejide OO, Li L, Cronin AM, Murillo A, Richardson PG, Anderson KC, Abel GA. Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018, 103:1380-9. 10.3324\/haematol.2018.187609","journal-title":"Haematologica"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01633-1","article-title":"MM-039 Unmet needs related to experiences of myeloma patients and their caregivers and potential solutions: a systemic literature review","volume":"24","author":"Dahal R","year":"2024","unstructured":"Dahal R, Abdal Khader AHS, Kasire SP, et al.. MM-039 Unmet needs related to experiences of myeloma patients and their caregivers and potential solutions: a systemic literature review. Clin Lymphoma Myeloma Leuk. 2024, 24:532. 10.1016\/S2152-2650(24)01633-1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster S","year":"2023","unstructured":"Forster S, Radpour R, Ochsenbein AF. Molecular and immunological mechanisms of clonal evolution in multiple myeloma. Front Immunol. 2023, 14:1243997. 10.3389\/fimmu.2023.1243997","journal-title":"Front Immunol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-212294","article-title":"Timing antigenic escape in multiple myeloma treated with t-cell redirecting immunotherapies","volume":"144","author":"Marios P","year":"2024","unstructured":"Marios P, Sungwoo A, Benjamin D, et al.. Timing antigenic escape in multiple myeloma treated with t-cell redirecting immunotherapies. Blood. 2024, 144:1899. 10.1182\/blood-2024-212294","journal-title":"Blood"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0545","article-title":"Identification of therapy-induced clonal evolution and resistance pathways in minimal residual clones in multiple myeloma through single-cell sequencing","volume":"30","author":"Cui J","year":"2024","unstructured":"Cui J, Li X, Deng S, et al.. Identification of therapy-induced clonal evolution and resistance pathways in minimal residual clones in multiple myeloma through single-cell sequencing. Clin Cancer Res. 2024, 30:3919-36. 10.1158\/1078-0432.CCR-24-0545","journal-title":"Clin Cancer Res"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities","volume":"13","author":"Botta C","year":"2021","unstructured":"Botta C, Mendicino F, Martino EA, et al.. Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities. Cancers (Basel). 2021, 13:3. 10.3390\/cancers13133213","journal-title":"Cancers (Basel)"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.36469\/001c.141714","article-title":"Cost of Anti-CD38 monoclonal antibodies in combination with bortezomib, lenalidomide and dexamethasone for the frontline treatment of transplant-ineligible patients with newly diagnosed multiple myeloma in the US","volume":"12","author":"Gupta-Werner N","year":"2025","unstructured":"Gupta-Werner N, Khare V, Macomson B, Medhekar R. Cost of Anti-CD38 monoclonal antibodies in combination with bortezomib, lenalidomide and dexamethasone for the frontline treatment of transplant-ineligible patients with newly diagnosed multiple myeloma in the US. J Health Econ Outcomes Res. 2025, 12:27-31. 10.36469\/001c.141714","journal-title":"J Health Econ Outcomes Res"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1200\/GO-24-00441","article-title":"Global access to multiple myeloma therapies","volume":"11","author":"Atallah R","year":"2025","unstructured":"Atallah R, Shatnawi Y, Ayoobkhan MF, et al.. Global access to multiple myeloma therapies. JCO Glob Oncol. 2025, 11:e2400441. 10.1200\/GO-24-00441","journal-title":"JCO Glob Oncol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2025.151848","article-title":"Different level and difficulties with financial burden in multiple myeloma patients and caregivers: a dyadic qualitative study","volume":"41","author":"Park Y","year":"2025","unstructured":"Park Y, Kim S, Kim N, et al.. Different level and difficulties with financial burden in multiple myeloma patients and caregivers: a dyadic qualitative study. Semin Oncol Nurs. 2025, 41:151848. 10.1016\/j.soncn.2025.151848","journal-title":"Semin Oncol Nurs"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00119","article-title":"Global myeloma trial participation and drug access in the era of novel therapies","volume":"8","author":"Fatoki RA","year":"2022","unstructured":"Fatoki RA, Koehn K, Kelkar A, et al.. Global myeloma trial participation and drug access in the era of novel therapies. JCO Glob Oncol. 2022, 8:e2200119. 10.1200\/GO.22.00119","journal-title":"JCO Glob Oncol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108735","article-title":"Machine learning and integrative multi-omics network analysis for survival prediction in acute myeloid leukemia","volume":"178","author":"Kosvyra \u0391","year":"2024","unstructured":"Kosvyra \u0391, Karadimitris \u0391, Papaioannou \u039c, Chouvarda I. Machine learning and integrative multi-omics network analysis for survival prediction in acute myeloid leukemia. Comput Biol Med. 2024, 178:108735. 10.1016\/j.compbiomed.2024.108735","journal-title":"Comput Biol Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115570","article-title":"Using proteomics data to identify personalized treatments in multiple myeloma: a machine learning approach","volume":"24","author":"Katsenou A","year":"2023","unstructured":"Katsenou A, O'Farrell R, Dowling P, Heckman CA, O'Gorman P, Bazou D. Using proteomics data to identify personalized treatments in multiple myeloma: a machine learning approach. Int J Mol Sci. 2023, 24:7. 10.3390\/ijms242115570","journal-title":"Int J Mol Sci"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13213372","article-title":"Current status and future of artificial intelligence in MM imaging: a systematic review","volume":"13","author":"Alipour E","year":"2023","unstructured":"Alipour E, Pooyan A, Shomal Zadeh F, Darbandi AD, Bonaffini PA, Chalian M. Current status and future of artificial intelligence in MM imaging: a systematic review. Diagnostics (Basel). 2023, 13:7. 10.3390\/diagnostics13213372","journal-title":"Diagnostics (Basel)"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.4065\/83.10.1142","article-title":"Treatment of myeloma: cure vs control","volume":"83","author":"Rajkumar SV","year":"2008","unstructured":"Rajkumar SV. Treatment of myeloma: cure vs control. Mayo Clin Proc. 2008, 83:1142-5. 10.4065\/83.10.1142","journal-title":"Mayo Clin Proc"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101116","article-title":"Aiming for the cure in myeloma: putting our best foot forward","volume":"62","author":"Bar N","year":"2023","unstructured":"Bar N, Firestone RS, Usmani SZ. Aiming for the cure in myeloma: putting our best foot forward. Blood Rev. 2023, 62:101116. 10.1016\/j.blre.2023.101116","journal-title":"Blood Rev"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0270","article-title":"Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma","volume":"19","author":"Berdeja JG","year":"2023","unstructured":"Berdeja JG, Cohen AD, Martin T, Madduri D, Pacaud L, Jagannath S. Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. Future Oncol. 2023, 19:1235-47. 10.2217\/fon-2023-0270","journal-title":"Future Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442292-recent-updates-and-advancements-in-the-diagnosis-and-management-of-plasma-cell-dyscrasias","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:04:05Z","timestamp":1768410245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442292-recent-updates-and-advancements-in-the-diagnosis-and-management-of-plasma-cell-dyscrasias"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":99,"URL":"https:\/\/doi.org\/10.7759\/cureus.101535","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,14]]}}}